Sammet, Stefanie
Touzeau-Römer, Veronique
Wolf, Eva
Schenk-Westkamp, Pia
Romano, Birgit
Gersbacher, Elke
Kastenbauer, Ulrich
Boesecke, Christoph
Rockstroh, Jürgen
Scholten, Stefan
Schneeweiss, Stephan
Roider, Julia
Seybold, Ulrich
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 27 April 2023
Accepted: 11 July 2023
First Online: 1 August 2023
Declarations
:
: S.S.: Advisory board honorarium from MSD. Travel/conference support from Gilead Sciences. E.W.: Honoraria for lectures, advisory boards or registration/travel expenses from AbbVie, Biogen, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. Involved in (research) projects supported by AbbVie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. C.B.: Honoraria for lectures and/or consultancies from AbbVie, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. J.Roc.: Honoraria for lectures and/or consultancies from AbbVie, Boehringer, Galapagos, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. S.Scho.: Speakers’ honoraria from ViiV, Gilead Sciences, Janssen, Cepheid. Honoraria for consultancies from Gilead Sciences, ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, INSTO, Heidelberg Therapeutics. S.Schn.: Speakers’ honoraria from ViiV, MSD, INSTO. Honoraria for consultancies from ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, Heidelberg Therapeutics. J.Roi.: Speakers’ honoraria from Gilead Sciences. Funding from DZIF, Else Kröner-Fresenius-Stiftung U.S.: Speakers’ honoraria from Gilead Sciences, ViiV, Janssen Cilag. Honoraria for consultancies from Gilead Sciences and ViiV. Travel/conference support from Gilead, ViiV. Poster award from Hector Stiftung. All other authors: no perceived potential conflict of interest.
: The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The study protocol has been approved by the Ethics Committee at Ludwig-Maximilians-Universität München (project number 21-0044) and all ethics committees responsible for the specific study sites. The study has been submitted to the German Registry for Clinical Studies (DRKS) with the ID 00030471. Written informed consent was obtained from all participants before inclusion into the study.